Evidence map›Paper›PMID 32461548›Full record

ArticleScientific reports2020

Author Correction: Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.

Bo Pan, Jing Shen, Jingyan Cao, Yongxu Zhou, Lihua Shang, Shi Jin, Shoubo Cao, Dehai Che, Fang Liu, Yan Yu

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bo PanDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Jing ShenDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Jingyan CaoDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Yongxu ZhouDepartment of general surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, P.R. China.
Lihua ShangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Shi JinDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Shoubo CaoDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Dehai CheDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Fang LiuDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China.
Yan YuDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, P.R. China. yuyan1291@126.com.
Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CNFourth Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32461548
PMCPMC7253409
OpenAlexW3031555510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.